study evaluating the efficacy and safety of intranasal administration of opn-375 in subjects with chronic rhinosinusitis with or without the presence of nasal polyps

Conditions: Chronic Rhinosinusitis

Summary: this is a 24-week randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate the efficacy and safety of intranasal administration of 186 and 372 μg twice daily (bid) of opn-375 in subjects with chronic rhinosinusitis (cs) with or without nasal polyps.

the primary objective of this study is to compare the efficacy of intranasal administration of twice-daily doses of 186 and 372 µg of opn-375 (fluticasone propionate) with placebo in subjects with chronic rhinosinusitis using the following co-primary endpoints: 1. a change from baseline in symptoms as measured by a composite score of nasal congestion, facial pain or pressure sensation, and nasal discharge (anterior and/or posterior) at the end of week 4. 2. a change from baseline to week 24/early termination (et) in the average percent of the volume opacified in the ethmoid and maxillary sinuses.

Eligibility criteria:
potential subjects must meet the following criteria to enter this study: 1. men or women aged 18 years and older at baseline visit 2. women of childbearing potential must be abstinent, or if sexually active, 1. be practicing an effective method of birth control (eg, prescription oral contraceptives, contraceptive injections, contraceptive patch, intrauterine device, double-barrier method \[eg, condoms, diaphragm, or cervical cap with spermicidal foam, cream, or gel\], or male partner sterilization) before entry and throughout the study, or 2. be surgically sterile (have had a hysterectomy or bilateral oophorectomy, tubal ligation, or otherwise be incapable of pregnancy), or 3. be postmenopausal (amenorrhea for at least 1 year) 3. women of child-bearing potential must have a negative urine pregnancy test at visit 1 (screening) 4. must have a history of chronic rhinosinusitis (crs) and be currently experiencing 2 or more of the following symptoms, 1 of which has to be either nasal congestion or nasal discharge (anterior and/or posterior nasal discharge) for equal to or greater than 12 weeks: * nasal congestion * nasal discharge (anterior and/or posterior nasal discharge) * facial pain or pressure * reduction or loss of smell 5. endoscopic evidence of nasal mucosal disease, with edema, purulent discharge, or polyps in middle meatus, bilaterally, or presence of bilateral disease on a prior computed tomography (ct) scan performed within 14 days of visit 1 6. must have confirmatory evidence via a ct scan of bilateral sinus disease (have at least 1 sinus on each side of nose with a lund-mackay score of ≥1) 7. baseline ct scan must show a combined ≥25% opacification of the ethmoid sinuses and ≥25% opacification of at least 1 maxillary sinus 8. must have at least moderate symptoms (as defined in protocol) of nasal congestion as reported by the subject, on average, for the 7-day period preceding visit 1 (screening) run-in 9. must have an average morning score of at least 1.5 for congestion on the nasal symptom scale (as defined in protocol) recorded on the subject diary over a 7-day period during the first 14 days of the single-blind run-in period 10. must demonstrate an ability to correctly complete the daily diary during the run-in period to be eligible for randomization 11. subjects with comorbid asthma or chronic obstructive pulmonary disorder (copd) must be stable with no exacerbations (eg, no emergency room visits, hospitalizations, or oral or parenteral steroid use) within the 3 months before visit 1 (screening). inhaled corticosteroid use must be limited to stable doses of no more than 1,000 μg/day of beclomethasone (or equivalent) for at least 3 months before visit 1 (screening) with plans to continue use throughout the study. 12. subjects with aspirin-exacerbated respiratory disease, who have undergone aspirin desensitization and are receiving daily aspirin therapy, must be receiving therapy for at least 6 months prior to visit 1. 13. must be able to cease treatment with intranasal steroids, inhaled corticosteroids (except permitted doses listed above for asthma and copd) at the screening visit 14. must be able to cease treatment with oral and nasal decongestants and antihistamines at visit 1 (screening) 15. must be able to use the exhalation delivery system (eds) correctly; all subjects will be required to demonstrate correct use with the practice eds at visit 1 (screening). 16. must be capable, in the opinion of the investigator, of providing informed consent to participate in the study. subjects must sign an informed consent document indicating that they understand the purpose of and procedures required for the study and are willing to participate in the study. potential subjects who meet any of the following criteria will be excluded from entering this study: 1. women who are pregnant or lactating 2. inability to have each nasal cavity examined for any reason, including nasal septum deviation 3. inability to achieve bilateral nasal airflow 4. is currently taking xhance® 5. have previously used xhance for more than 1 month and did not achieve an adequate symptomatic response 6. the nasal/sinus anatomy prevents the accurate assessment of sinus volume via ct scan 7. history of sinus or nasal surgery within 6 months before visit 1 or has not healed from a prior sinus or nasal surgery 8. have current evidence of odontogenic sinusitis, sinus mucocele (the affected sinus is completely opacified and either the margins are expanded and/or thinned or there are areas of complete bone resorption resulting in bony defect and extension of the "mass" into adjacent tissues), evidence of allergic fungal sinusitis, or evidence of complicated sinus disease (including, but not limited to, extension of inflammation outside of the sinuses and nasal cavity) 9. have a paranasal sinus or nasal tumor 10. have a polyp extending outside the ostiomeatal complex/middle turbinate (anterior or inferior) that is below the inferior turbinate attachment as determined by the nasoendoscopy at screening 11. have a nasal septum perforation 12. have had more than 1 episode of epistaxis with frank bleeding in the month before visit 1 (screening) 13. have evidence of significant mucosal injury, ulceration (eg, exposed cartilage) on visit 1 (screening) nasal examination/nasoendoscopy 14. have current, ongoing rhinitis medicamentosa (rebound rhinitis) 15. have significant oral structural abnormalities (eg, a cleft palate) 16. have a diagnosis of cystic fibrosis 17. history of eosinophilic granulomatosis with polyangiitis (churg-strauss syndrome) or dyskinetic ciliary syndromes 18. symptom resolution or last dose of antibiotics for purulent nasal infection, acute sinusitis, or upper respiratory tract infection, influenza, or sars-cov-2 (covid-19) has not occurred before visit 1 or was less than 4 weeks before the ct scan. potential subjects presenting with any of these infections may be rescreened 4 weeks after symptom resolution. 19. planned sinonasal surgery during the period of the study 20. allergy, hypersensitivity, or contraindication to corticosteroids or steroids 21. has used oral steroids in the past for treatment of crs and did not experience any relief of symptoms 22. has a steroid eluting sinus stent still in place within 30 days of visit 1 23. allergy or hypersensitivity to any excipients in study drug 24. exposure to any glucocorticoid treatment with potential for systemic effects (eg, oral, parenteral, intra-articular, or epidural steroids, high dose topical steroids) within 1 month before visit 1 (screening); except as noted in inclusion criteria for subjects with comorbid asthma or copd 25. have nasal candidiasis 26. history or current diagnosis of any form of glaucoma or ocular hypertension 27. history of intraocular pressure (iop) elevation on any form of steroid therapy 28. history or current diagnosis of the presence (in either eye) of a cataract unless both natural intraocular lenses have been removed 29. history of immunodeficiency 30. any serious or unstable concurrent disease, psychiatric disorder, or any significant condition that, in the opinion of the investigator could confound the results of the study or could interfere with the subject's participation or compliance in the study 31. have a positive drug screen or a recent (within 1 year of visit 1 \[screening\]) history of drug or alcohol abuse, or dependence that, in the opinion of the investigator could interfere with the subject's participation or compliance in the study 32. have participated in an investigational drug clinical trial within 30 days of visit 1 (screening) 33. have received mepolizumab (nucala®), reslizumab (cinquair®), dupilumab (dupixent®), omalizumab (xolair®), or benralizumab (fasenra™) within 6 months of visit 1 (screening) 34. is using strong cytochrome p450 3a4 (cyp3a4) inhibitor (eg, ritonavir, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, saquinavir, ketoconazole, telithromycin, conivaptan, lopinavir, voriconazole, cobicistat) 35. is an employee of the investigator or study center, with direct involvement in the proposed study or other studies under the direction of that investigator or study center, or is a family member of the employee or the investigator 36. patients who report unexplained worsening of vision within the past 3 months (e.g. difficulty reading or seeing traffic signs from a distance.). a diagnosis of presbyopia established by an eye doctor is not exclusionary